definiens: shall mean any treatment, whether a product or a service, that utilizes cells or tissues that a re manipulated and/or expanded ex vivo, prior to use as a therapeutic age nt to treat any injury, disease or other condition, and which includes or i s produced using a Contributed Product, including without limitation, CB001, prior to the earlier of the exercise of the Option or the expiration of the Option Period with respect to such treatment . For the avoidance of dou bt, once [COMPANY] exercises its Option with respect to a Cell Therapy Product, such Cell Therapy Product shall be deemed a Collaboration Product and shall cease t o be considered a Cell Therapy Product . For the avoidance of doubt, once t he Option Period expires with respect to a Cell Therapy Product for an indic ation such Cell Therapy Product for that indication shall be deemed an Unop tioned Cell Therapy Product and shall cease to be considered a Cell Therapy Pro duct